Funder
National Natural Science Foundation of China
Shanghai Hospital Development Center
Shanghai Sailing Program
Shanghai Science and Technology Development Foundation
Publisher
Springer Science and Business Media LLC
Reference22 articles.
1. Mitry D, Bunce C, Charteris D. Anti-vascular endothelial growth factor for macular edema secondary to branch retinal vein occlusion. Cochrane Database Syst Rev. 2013. https://doi.org/10.1002/14651858.CD009510.pub2.
2. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(1102–12): e1.
3. Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011;118:1594–602.
4. Tadayoni R, Waldstein SM, Boscia F, et al. Individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion: six-month results of brighter. Ophthalmology. 2016;123:1332–44.
5. Brynskov T, Kemp H, Sorensen TL. Intravitreal ranibizumab for retinal vein occlusion through 1 year in clinical practice. Retina. 2014;34:1637–43.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献